Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
leg veins chronic venous disease PAD peripheral artery disease

Drug-coated balloons make little impact on PAD outcomes

Researchers tracked data from more than 3,000 patients, calling for more clinical trials of antiproliferative agents other than paclitaxel.

Thumbnail

No sedation required: Local anesthesia enough for most TAVR patients

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

Abbott's Navitor TAVR valve

Abbott receives expanded approval for Navitor TAVR system

Abbott's TAVR valve now has CE mark approval for treating low-, intermediate- and high-risk patients who present with symptomatic severe aortic stenosis. The news comes as new data on the valve's safety and effectiveness were just published in JACC: Cardiovascular Interventions.

Recor Medical's Paradise Ultrasound Renal Denervation System

Recor Medical gains historic approval for its ultrasound RDN system

Recor Medical's Paradise Ultrasound Renal Denervation System is the first medical device approved for the treatment of hypertension in Japan. It first gained FDA approval back in 2023.

Edwards Lifesciences gains CE mark approval for Evoque transcatheter tricuspid valve replacement (TTVR) system

Old age, RBBB help predict when TTVR patients may require a permanent pacemaker

Though just a small, single-facility study, these findings help care teams know what to look for when performing transcatheter tricuspid valve replacement.

Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

Medtronic receives updated FDA approval for redo TAVR

The company also launched a new clinical trial designed to follow redo TAVR patients who present with symptomatic bioprosthetic valve failure for up to five years.

San Francisco TCT 2025

CRF unveils late-breaking clinical trials for TCT 2025 in San Francisco

This year marks the 37th annual gathering of the popular Transcatheter Cardiovascular Therapeutics conference. What started as a small gathering in 1988 has grown into one of interventional cardiology’s biggest events.

Johnson & Johnson MedTech Automated Impella Controller

FDA details new risk with Johnson & Johnson heart pump controllers after patient’s death

This latest alert was put in place after Johnson & Johnson MedTech learned that some of its Automated Impella Controllers were built to the wrong specifications, impacting their ability to function. Affected devices should not be used going forward.

Displaying 33 - 40 of 1216
Design by Adaptive Theme